NBT Analytics
EEG analysis for clinical trials.
| USD | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | (83 %) |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
NBT Analytics BV, a spin-off from VU Amsterdam, specializes in enhancing CNS (Central Nervous System) drug development through innovative EEG (electroencephalogram) technology. Founded in August 2015 by Dr. Klaus Linkenkaer Hansen and Dr. Simon Shlomo Poil, the company focuses on providing detailed insights into how drugs affect brain activity. By utilizing a comprehensive selection of EEG biomarkers and identifying drug-specific indices, NBT Analytics achieves greater accuracy in classifying drug or disease-induced changes in brain activity compared to single biomarker analyses. The company primarily serves pharmaceutical companies and research institutions involved in CNS drug development. Operating within the neuroscience and pharmaceutical markets, NBT Analytics employs a business model that includes offering analytical services and licensing its proprietary technology. Revenue is generated through service fees and technology licensing agreements.
Keywords: EEG biomarkers, CNS drug development, brain activity, pharmaceutical research, neuroscience, drug-specific indices, analytical services, technology licensing, VU Amsterdam, innovative EEG.